Literature DB >> 19688130

Altered expression of Smad proteins in T or NK-cell lymphomas.

Jai Hyang Go1.   

Abstract

PURPOSE: Smad proteins mediate cellular signaling through the transforming growth factor-beta family (TGF-betas). Smads 2 and 3 transmit signals from TGF-beta, and Smad4 is a common mediator, as well. However, little is known concerning the expression patterns of Smads in lymphoid tissue.
MATERIALS AND METHODS: Immunohistochemistry for Smad3 and Smad4 was performed on paraffin-embedded tissue sections collected from 26 T- or NK-cell lymphomas.
RESULTS: Nearly all cells in germinal centers were positive for Smad3, and more than 50% of paracortical cells were positive for Smad3 in reactive lymphoid tissue. When Smad4 immunostaining was conducted, nearly all the cells in the germinal centers showed diffuse cytoplasmic staining, and most of them exhibited nuclear positivity, as well. In addition, more than 50% of the cells in the paracortex were positive for Smad4. Furthermore, the Smad3 staining pattern was preserved in all malignant lymphomas, but four of these cases (15%) exhibited decreased expression of Smad4. All lymphoblastic lymphomas showed strong positivity in most of tumor cells, but one unspecified peripheral lymphoma, two nasal NK/T cell lymphomas, and one anaplastic large cell lymphoma were negative for Smad4.
CONCLUSIONS: These results suggest that TGF-beta-specific Smads may be actively involved in signal transduction in lymphoid organs and that Smad-mediated TGF-beta signaling pathways are operative in malignant lymphoma. In addition, loss of Smad4 expression might be associated with development of some T-cell lymphomas.

Entities:  

Keywords:  Etiology; Lymphoma; Smad proteins; T lymphocytes

Year:  2008        PMID: 19688130      PMCID: PMC2697478          DOI: 10.4143/crt.2008.40.4.197

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  21 in total

1.  Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes.

Authors:  K Takaku; M Oshima; H Miyoshi; M Matsui; M F Seldin; M M Taketo
Journal:  Cell       Date:  1998-03-06       Impact factor: 41.582

2.  A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.

Authors:  P I Knaus; D Lindemann; J F DeCoteau; R Perlman; H Yankelev; M Hille; M E Kadin; H F Lodish
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

Review 3.  TGF-beta receptors and signal transduction.

Authors:  K Miyazono
Journal:  Int J Hematol       Date:  1997-02       Impact factor: 2.490

Review 4.  Transforming growth factor-beta signaling in normal and malignant hematopoiesis.

Authors:  S-J Kim; J Letterio
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

5.  Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease.

Authors:  S M Hsu; J Lin; S S Xie; P L Hsu; S Rich
Journal:  Hum Pathol       Date:  1993-03       Impact factor: 3.466

6.  Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease.

Authors:  M E Kadin; B A Agnarsson; L R Ellingsworth; S R Newcom
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

7.  Decreased expression of TGF-beta type 2 receptor in primary B-cell lymphomas of the stomach.

Authors:  Jai Hyang Go
Journal:  Pathol Res Pract       Date:  2002       Impact factor: 3.250

8.  Loss of receptors for transforming growth factor beta in human T-cell malignancies.

Authors:  M E Kadin; M W Cavaille-Coll; R Gertz; J Massagué; S Cheifetz; D George
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.

Authors:  Alexander Rosendahl; Matthaios Speletas; Karin Leandersson; Fredrik Ivars; Paschalis Sideras
Journal:  Int Immunol       Date:  2003-12       Impact factor: 4.823

10.  Loss of Smad3 in acute T-cell lymphoblastic leukemia.

Authors:  Lawrence A Wolfraim; Tania M Fernandez; Mizuko Mamura; Walter L Fuller; Rajesh Kumar; Diane E Cole; Stacey Byfield; Angelina Felici; Kathleen C Flanders; Thomas M Walz; Anita B Roberts; Peter D Aplan; Frank M Balis; John J Letterio
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

View more
  2 in total

1.  Association between Altered Expression and Genetic Variations of Transforming Growth Factor β-Smad Pathway with Chronic Myeloid Leukemia.

Authors:  Yogender Shokeen; Neeta Raj Sharma; Abhishek Vats; Veronique Dinand; Mirza Adil Beg; Satish Sanskaran; Sachin Minhas; Mayank Jauhri; Arun K Hariharan; Vibha Taneja; Shyam Aggarwal
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-01-01

2.  Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review.

Authors:  Karen E Wain; Marissa S Ellingson; Jamie McDonald; Amanda Gammon; Maegan Roberts; Pavel Pichurin; Ingrid Winship; Douglas L Riegert-Johnson; Jeffrey N Weitzel; Noralane M Lindor
Journal:  Genet Med       Date:  2014-02-13       Impact factor: 8.822

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.